PURPOSE:ABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity. We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced or metastatic non-small-cell lung cancer (NSCLC). METHODS:One hundred seventy-one patients receivedintravenous pemetrexed 500 mg/m(2) day 1 and oral ABT-751 or placebo days 1 to 14 of 21-day cycles. The primary end point was progression-free survival (PFS). Secondary end point included overall survival (OS); pharmacokinetic and pharmacodynamic parameters were also analyzed. RESULTS: The recommended phase II dose of ABT-751 with pemetrexed is 200 mg. Fatigue, constipation, anemia, nausea, and diarrhea were the most common toxicities in both study arms. No pharmacokinetic interactions were observed. Median PFS in the ABT-751 arm was 2.3 months versus 1.9 for placebo (P = .819, log-rank) for the intention-to-treat population. However, differences in PFS (P = .112, log-rank) and OS (P = .034, log-rank; median 3.3 v 8.1 months) favoring ABT-751 were seen in the squamous NSCLC subgroup. Baseline circulating tumor cell concentrations were predictive of improved OS (P = .013). Changes from baseline of greater than 20% in plasma levels of placenta growth factor (P = .056), squamous cell carcinoma antigen (P = .03), and cytokeratin 19 fragment antigen 21-1 (P = .01) were markers best associated with improved OS. CONCLUSION: Addition of ABT-751 to pemetrexed is well-tolerated, but does not improve outcome in unselected patients with recurrent NSCLC. ABT-751 may have therapeutic potential in squamous NSCLC. Exploratory cellular and molecular analyses in this study identified biomarkers that may correlate with survival.
RCT Entities:
PURPOSE:ABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity. We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced or metastatic non-small-cell lung cancer (NSCLC). METHODS: One hundred seventy-one patients received intravenous pemetrexed 500 mg/m(2) day 1 and oral ABT-751 or placebo days 1 to 14 of 21-day cycles. The primary end point was progression-free survival (PFS). Secondary end point included overall survival (OS); pharmacokinetic and pharmacodynamic parameters were also analyzed. RESULTS: The recommended phase II dose of ABT-751 with pemetrexed is 200 mg. Fatigue, constipation, anemia, nausea, and diarrhea were the most common toxicities in both study arms. No pharmacokinetic interactions were observed. Median PFS in the ABT-751 arm was 2.3 months versus 1.9 for placebo (P = .819, log-rank) for the intention-to-treat population. However, differences in PFS (P = .112, log-rank) and OS (P = .034, log-rank; median 3.3 v 8.1 months) favoring ABT-751 were seen in the squamous NSCLC subgroup. Baseline circulating tumor cell concentrations were predictive of improved OS (P = .013). Changes from baseline of greater than 20% in plasma levels of placenta growth factor (P = .056), squamous cell carcinoma antigen (P = .03), and cytokeratin 19 fragment antigen 21-1 (P = .01) were markers best associated with improved OS. CONCLUSION: Addition of ABT-751 to pemetrexed is well-tolerated, but does not improve outcome in unselected patients with recurrent NSCLC. ABT-751 may have therapeutic potential in squamous NSCLC. Exploratory cellular and molecular analyses in this study identified biomarkers that may correlate with survival.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Ann M Mauer; Ezra E W Cohen; Patrick C Ma; Mark F Kozloff; Lee Schwartzberg; Andrew I Coates; Jiang Qian; Anne E Hagey; Gary B Gordon Journal: J Thorac Oncol Date: 2008-06 Impact factor: 15.609
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Tian Ma; Alexander D Fuld; James R Rigas; Anne E Hagey; Gary B Gordon; Ethan Dmitrovsky; Konstantin H Dragnev Journal: Chemotherapy Date: 2012-11-12 Impact factor: 2.544
Authors: Charles M Rudin; Christine L Hann; Edward B Garon; Moacyr Ribeiro de Oliveira; Philip D Bonomi; D Ross Camidge; Quincy Chu; Giuseppe Giaccone; Divis Khaira; Suresh S Ramalingam; Malcolm R Ranson; Caroline Dive; Evelyn M McKeegan; Brenda J Chyla; Barry L Dowell; Arunava Chakravartty; Cathy E Nolan; Niki Rudersdorf; Todd A Busman; Mack H Mabry; Andrew P Krivoshik; Rod A Humerickhouse; Geoffrey I Shapiro; Leena Gandhi Journal: Clin Cancer Res Date: 2012-04-11 Impact factor: 12.531
Authors: Federico Innocenti; Jacqueline Ramírez; Jennifer Obel; Julia Xiong; Snezana Mirkov; Yi-Lin Chiu; David A Katz; Robert A Carr; Wei Zhang; Soma Das; Araba Adjei; Ann M Moyer; Pei Xian Chen; Andrew Krivoshik; Diane Medina; Gary B Gordon; Mark J Ratain; Leonardo Sahelijo; Richard M Weinshilboum; Gini F Fleming; Anahita Bhathena Journal: Pharmacogenet Genomics Date: 2013-07 Impact factor: 2.089
Authors: Rosalyn A Juergens; John Wrangle; Frank P Vendetti; Sara C Murphy; Ming Zhao; Barbara Coleman; Rosa Sebree; Kristen Rodgers; Craig M Hooker; Noreli Franco; Beverly Lee; Salina Tsai; Igor Espinoza Delgado; Michelle A Rudek; Steven A Belinsky; James G Herman; Stephen B Baylin; Malcolm V Brock; Charles M Rudin Journal: Cancer Discov Date: 2011-11-09 Impact factor: 39.397
Authors: Suresh S Ramalingam; Mikhail Shtivelband; Ross A Soo; Carlos H Barrios; Anatoly Makhson; José G M Segalla; Kenneth B Pittman; Petr Kolman; Jose R Pereira; Gordan Srkalovic; Chandra P Belani; Rita Axelrod; Taofeek K Owonikoko; Qin Qin; Jiang Qian; Evelyn M McKeegan; Viswanath Devanarayan; Mark D McKee; Justin L Ricker; Dawn M Carlson; Vera A Gorbunova Journal: J Clin Oncol Date: 2015-01-05 Impact factor: 44.544
Authors: Michelle A Rudek; Arvind Dasari; Daniel Laheru; Ping He; Runyan Jin; Rosalind Walker; Gretchen E Taylor; Antonio Jimeno; Ross C Donehower; Manuel Hidalgo; Wells A Messersmith; W Thomas Purcell Journal: J Clin Pharmacol Date: 2016-02-02 Impact factor: 3.126